Literature DB >> 19457299

The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms.

Abebaw Fekadu1, Sarah C Wooderson, Kalypso Markopoulou, Anthony J Cleare.   

Abstract

OBJECTIVE: A recently proposed multidimensional method of staging treatment resistance in depression, the Maudsley Staging Method (MSM), has been shown to predict short-term outcome of treatment. This study tested whether the MSM predicts longer-term clinical outcome. We hypothesized that patients with higher scores on the MSM would experience a worse longer-term outcome in terms of time spent in a depressive episode and level of functional impairment.
METHOD: From May through July of 2008, we followed up patients with treatment-resistant depression discharged from an inpatient unit of an affective disorders service; all had MSM scores previously calculated from preadmission clinical data. We used the Longitudinal Interval Follow-up Evaluation (LIFE) chart to determine the monthly symptomatic course of depression blind to initial MSM scores. We employed a regression model to adjust for various confounding factors, including variable duration of follow-up, to determine the independent association of MSM scores with persistence of depressive disorder.
RESULTS: We assessed 62 of 80 eligible patients (78%) in a median follow-up duration (interquartile range) of 29.5 (19.0-52.5) months. The MSM independently predicted (1) being in an episode for 50% or longer of the follow-up duration (OR = 2.11, 95% CI = 1.25 to 3.57), (2) being in an episode at the time of follow-up assessment (OR = 1.89, 95% CI = 1.17 to 3.05), (3) being persistently in an episode throughout the follow-up period (OR = 2.01, 95% CI = 1.14 to 3.54), and (4) total months spent in a depressive episode (OR = 1.22, 95% CI = 1.06 to 1.40). The MSM also predicted functional impairment. Antidepressant count and the Thase and Rush model did not independently predict persistence of depression or functional impairment.
CONCLUSION: The MSM appears to have reasonable predictive validity regarding the longer-term course of illness, particularly persistence of depressive episodes. The MSM may be a useful, and possibly an improved, alternative to existing models of staging of treatment-resistant depression. ©Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457299     DOI: 10.4088/JCP.08m04728

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  27 in total

1.  Quality of life across domains among individuals with treatment-resistant depression.

Authors:  Heidemarie Lex; Yarden Ginsburg; Adam F Sitzmann; Clara Grayhack; Daniel F Maixner; Brian J Mickey
Journal:  J Affect Disord       Date:  2018-09-19       Impact factor: 4.839

2.  Are Concerns About Irremediableness, Vulnerability, or Competence Sufficient to Justify Excluding All Psychiatric Patients from Medical Aid in Dying?

Authors:  William Rooney; Udo Schuklenk; Suzanne van de Vathorst
Journal:  Health Care Anal       Date:  2018-12

3.  High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression.

Authors:  Nolan R Williams; Keith D Sudheimer; Brandon S Bentzley; Jaspreet Pannu; Katy H Stimpson; Dalton Duvio; Kirsten Cherian; Jessica Hawkins; Kristen H Scherrer; Benjamin Vyssoki; Danielle DeSouza; Kristin S Raj; Jennifer Keller; Alan F Schatzberg
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

4.  Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.

Authors:  Richard Musil; Florian Seemüller; Sebastian Meyer; Ilja Spellmann; Mazda Adli; Michael Bauer; Klaus-Thomas Kronmüller; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Robert Fisher; Wolfgang Gaebel; Rebecca Schennach; Hans-Jürgen Möller; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-14       Impact factor: 4.035

5.  The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment.

Authors:  Mario F Juruena; Anthony J Cleare; Andrew S Papadopoulos; Lucia Poon; Stafford Lightman; Carmine M Pariante
Journal:  Psychoneuroendocrinology       Date:  2010-06-16       Impact factor: 4.905

6.  Distinct predictors of short- versus long-term depression outcomes following electroconvulsive therapy.

Authors:  Brian J Mickey; Yarden Ginsburg; Erica Jensen; Daniel F Maixner
Journal:  J Psychiatr Res       Date:  2021-12-14       Impact factor: 5.250

7.  A randomized controlled trial of brief and ultrabrief pulse right unilateral electroconvulsive therapy.

Authors:  Colleen K Loo; Natalie Katalinic; Deirdre J Smith; Anna Ingram; Nathan Dowling; Donel Martin; Kerryn Addison; Dusan Hadzi-Pavlovic; Brett Simpson; Isaac Schweitzer
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-05       Impact factor: 5.176

Review 8.  Mechanisms of antidepressant resistance.

Authors:  Wissam El-Hage; Samuel Leman; Vincent Camus; Catherine Belzung
Journal:  Front Pharmacol       Date:  2013-11-22       Impact factor: 5.810

9.  Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study): study protocol for a randomised clinical trial.

Authors:  Atsuo Nakagawa; Mitsuhiro Sado; Dai Mitsuda; Daisuke Fujisawa; Toshiaki Kikuchi; Takayuki Abe; Yuji Sato; Satoru Iwashita; Masaru Mimura; Yutaka Ono
Journal:  BMJ Open       Date:  2014-10-21       Impact factor: 2.692

10.  Predicting outcome following psychological therapy in IAPT (PROMPT): a naturalistic project protocol.

Authors:  Nina Grant; Matthew Hotopf; Gerome Breen; Anthony Cleare; Nick Grey; Nilay Hepgul; Sinead King; Paul Moran; Carmine M Pariante; Janet Wingrove; Allan H Young; André Tylee
Journal:  BMC Psychiatry       Date:  2014-06-09       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.